Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28178923
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Non-neuronal cholinergic activity is potentiated in myasthenia gravis.
Han B1, Zhang C1, Liu S2, Xia Y3, Sun H4, Gong Z5, Simard AR6, Liu Q1,7, Hao J8.
BMC Neurol. 2017 Feb 8;17(1):28. doi: 10.1186/s12883-016-0772-3.
- BACKGROUND:
Non-neuronal acetylcholine (ACh) restricts autoimmune responses and
attenuates inflammation by cholinergic anti-inflammation pathway. To date, the
implication of ACh in myasthenia gravis (MG) remained unexplored. This study
aimed to investigate the possible relationship between ACh levels,
anti-muscle-specific tyrosine kinase (MuSK) antibody titers, main clinical
features and outcomes of MG patients.
- METHODS:
We successfully measured ACh levels in human peripheral blood
mononuclear cells (PBMCs) from 125 MG patients and 50 matched healthy controls by
using ultra-performance liquid chromatography-tandem mass spectrometry
(UPLC-MS/MS). We assessed the quantitative MG (QMG) scores for each patient and
titered anti-MuSK antibody.
- RESULTS:
We found that PBMC-derived ACh level was significantly higher in MG
patients, especially in patients of class III, IV-V, compared with that in
controls (0.142 ± 0.108 vs. 0.075 ± 0.014 ng/million cells, p = 0.0003) according
to the Myasthenia Gravis Foundation of America clinical classification.
Importantly, we also found that ACh levels were positively correlated with QMG
scores (r = 0.83, p < 0.0001) and anti-MuSK Ab levels (r = 0.85, p < 0.0001).
- CONCLUSIONS:
Our demonstration of elevated ACh levels in PBMCs of MG patients
foreshadows potential new avenues for MG research and treatment.